The partnership will connect Evogene’s AI-based ChemPass AI with the BCDD’s laboratory infrastructure.

RNA interference is a natural mechanism for living cells to control whether specific genes are being used or not.

June 30 (Reuters) - Hong Kong-listed drug design tech firm Metis TechBio said on Tuesday it has granted U.S.-based biotechnology firm Boulevard Bio exclusive global rights to develop, manufacture and ...

The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...

When machine learning is used to suggest new potential scientific insights or directions, algorithms sometimes offer solutions that are not physically sound. Take, for example, AlphaFold, the AI ...

Despite significant progress in medicinal chemistry and life sciences research, drug discovery and development remain slow and expensive, taking on average approximately 15 years and US$2 billion to ...

Incubated by Houston-based Fannin Innovation Studio, the 11h drug created in Nebraska will move toward phase 1 clinical ...

The in silico protein design market offers key opportunities in AI-driven drug discovery, personalized medicine, and automation in biological research. With cloud-based simulation growth, partnerships ...

Google DeepMind announced the launch of AlphaProteo, an AI system to help biological and health researchers design novel, high-strength proteins that bind to target molecules with accuracy and ...

Experts have been raising concerns about “AI washing.” One of these experts, futurist Bernard Marr, has said that AI washing “involves exaggerating the capabilities of a product or service that is ...